CC
VRTX icon

Centiva Capital’s Vertex Pharmaceuticals VRTX Stock Holding History

Centiva Capital’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-50,200
Closed -$22.8M – 2053
2025
Q4 		$22.8M Sell
50,200
-50,000
-50% -$21.6M 0.19% 93
2025
Q3 		$39.2M Buy
+100,200
New +$41.9M 0.37% 47
2025
Q1 		– Sell
-600
Closed -$242K – 2184
2024
Q4 		$242K Sell
600
-400
-40% -$185K 0.01% 1267
2024
Q3 		$465K Hold
1,000
– – 0.01% 1295
2024
Q2 		$469K Sell
1,000
-100
-9% -$43.4K 0.01% 1194
2024
Q1 		$460K Sell
1,100
-8,000
-88% -$3.38M 0.01% 1032
2023
Q4 		$3.7M Buy
9,100
+100
+1% +$36.9K 0.09% 218
2023
Q3 		$3.13M Buy
9,000
+2,500
+38% +$874K 0.07% 259
2023
Q2 		$2.29M Hold
6,500
– – 0.05% 339
2023
Q1 		$2.05M Sell
6,500
-14,000
-68% -$4.2M 0.05% 398
2022
Q4 		$5.92M Sell
20,500
-5,000
-20% -$1.52M 0.17% 126
2022
Q3 		$7.38M Buy
25,500
+12,000
+89% +$3.45M 0.14% 97
2022
Q2 		$3.8M Sell
13,500
-600
-4% -$161K 0.09% 195
2022
Q1 		$3.68M Buy
14,100
+9,100
+182% +$2.16M 0.07% 244
2021
Q4 		$1.1M Buy
+5,000
New +$972K 0.02% 580
2021
Q3 		– Sell
-5,000
Closed -$1.01M – 1634
2021
Q2 		$1.01M Buy
+5,000
New +$1.05M 0.02% 567
2020
Q4 		– Sell
-4,100
Closed -$1.11M – 1122
2020
Q3 		$1.11M Hold
4,100
– – 0.07% 186
2020
Q2 		$1.19M Sell
4,100
-3,400
-45% -$922K 0.07% 151
2020
Q1 		$1.78M Buy
+7,500
New +$1.72M 0.08% 153
2019
Q2 		– Sell
-1,500
Closed -$276K – 512
2019
Q1 		$276K Buy
+1,500
New +$277K 0.02% 263

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Centiva Capital's VRTX Position: Q2 2026 in Review

Centiva Capital sold out of Vertex Pharmaceuticals (VRTX) in Q2 2026, closing a stake of 2,147 shares — an estimated $959K sold.

Centiva Capital first reported a position in VRTX in Q1 2019 and held it in 22 quarters. The position peaked at $3.68M in Q2 2023. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Centiva Capital reported no remaining Vertex Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Centiva Capital sold 2,147 Vertex Pharmaceuticals shares in Q2 2026, an estimated $959K.
  • Centiva Capital first reported a position in Vertex Pharmaceuticals in Q1 2019 and held it in 22 quarters.
  • Centiva Capital's Vertex Pharmaceuticals position peaked at $3.68M in Q2 2023.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.